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- We present an updated summary on ZnPcs as antitumor photosensitizers  
- ZnPcs localized in lysosomes, mitochondria or ER are efficient antitumor agents 
- Apoptosis, necrosis and autophagy are the main cellular responses induced by 
ZnPc PDT  
- Current efforts to improve in vivo PDT treatments with ZnPcs are discussed 















Photodynamic therapy (PDT) is a highly specific and clinically approved method for cancer 
treatment in which a nontoxic drug known as photosensitizer (PS) is administered to a 
patient. After selective tumor irradiation, an almost complete eradication of the tumor can be 
reached as a consequence of reactive oxygen species (ROS) generation, which not only 
damage tumor cells, but also lead to tumor-associated vasculature occlusion and the 
induction of an immune response. Despite exhaustive investigation and encouraging results, 
zinc(II) phthalocyanines (ZnPcs) have not been approved as PSs for clinical use yet. This 
review presents an overview on the physicochemical properties of ZnPcs and biological 
results obtained both in vitro and in more complex models, such as 3D cell cultures, chicken 
chorioallantoic membranes and tumor-bearing mice. Cell death pathways induced after PDT 
treatment with ZnPcs are discussed in each case. Finally, combined therapeutic strategies 
including ZnPcs and the currently available clinical trials are mentioned. 
 
Abbreviations: AIF, apoptosis-inducing factor; DCF-DA, 2´,7´-dichlorfluorescein 
diacetate; EGFR, epidermal growth factor receptor; ER, endoplasmic reticulum; FAAD, 
Fas-associated death domian;  GA, Golgi apparatus; LDH, Lactate dehydrogenase; NP, 
nanoparticles; PARP, poly(ADP-ribose) polymerase; PDT, photodynamic therapy; PEG, 
polyethylene glycol; PS, photosensitizer; Pcs, phthalocyanines; ROS, reactive oxygen 
species; UCNPs, upconverting nanoparticles; ZnPcs, zinc(II) phthalocyanines; ZnNcs, 
zinc(II)-naphthalocyanines.   
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The first approaches to photodynamic therapy (PDT) are found in ancient texts such 
as the Egyptian medical treatise Ebers Papyrus and the Atharvaveda from the Hinduism. 
Despite this background, the observation of photochemical sensitization of tissues was first 
performed in detail by Raab (1900) in Germany and shortly afterwards by Von Tappeiner 
(1900), who coined the term "photodynamic action" to describe the treatment of skin tumors 
by using topical administration of eosin combined with sunlight (Kou et al., 2017). PDT is a 
therapeutic procedure based on the administration of a non-toxic photosensitizer (PS), which 
after activation by visible light in the presence of molecular oxygen, produces cytotoxic 
reactive oxygen species (ROS) that lead to cell damage (Henderson and Dougherty, 1992; 
Sharman et al., 1999; Detty et al., 2004; Plaetzer et al., 2009). Since the PS is preferentially 
localized into the cells to be treated and is activated only after irradiation of these cells, the 
PDT is a selective procedure frequently used for the treatment of a diversity of 
dermatological, ophthalmic and oncological diseases (Agostinis et al., 2011; van Straten et 
al., 2017). In clinical use, after topical or intravenous administration of a PS, the patient is 
irradiated with light of a suitable wavelength in the area to be treated and then maintained in 












from the organism will allow the patient to resume usual activities with exposure to both 
solar and artificial light.  
At molecular level, light irradiation at a specific wavelength delivers the necessary 
energy to produce an electronic transition of the PS from its ground state to an excited singlet 
state of short half-life. The loss of energy caused by the return of electrons from the excited 
level to the basal energy level (deactivation process) may involve fluorescence/heat emission 
or intersystem crossing to generate a lower energy excited triplet state. Deactivation of this 
triplet species can occur mainly by two mechanisms, known as type I or type II reactions, 
that generate reactive oxygen species (ROS) (Agostinis et al., 2011; Oliveira et al., 2011; 
Gomes et al., 2018). In type I reactions, the PS transfers an electron to biological substrates 
to form free radicals, which finally give rise to cytotoxic species such as superoxide anion, 
hydrogen peroxide and hydroxyl radicals. In type II reactions, the triplet oxygen (3O2) is 
converted into singlet oxygen (1O2), a highly cytotoxic species with a very short half-life, 
between 10 and 320 ns (Agostinis et al., 2011). As this species can diffuse 10-55 nm on 
average, a distance that represents one thousandth of the diameter of eukaryotic cells, the 
intracellular organelles containing the PS are considered to be the main sites where the 
phototoxic damage is triggered. The final consequence of the ROS formation is the induction 
of a cell death process, the destruction of the microvasculature and the activation of a local 
inflammatory reaction that may trigger an immune response (Engbreht et al., 1999; Castano 
et al., 2006; Buytaert et al, 2007; van Straten et al., 2017).  
Many photo-activable molecules, including porphyrins, phthalocyanines, chlorines 
and bacteriochlorine derivatives, among others, have been found to be useful candidates for 
PDT applications (Gomes et al., 2018; Kou et al., 2017). In the 70´s, the use of PDT as a 
therapeutic option generated a renewed interest in the oncological field from the performance 











1978) carried out the first clinical trial in patients with Photofrin as photosensitizer. This 
PS together with other porphyrin derivatives formed the first generation of PSs. This group 
of PSs showed some unfavourable characteristics, including low absorptions in the red light 
region (range between 600 to 800 nm, where tissue light penetration is high), poor solubility 
in polar solvents and skin phototoxicity (Allison and Sibata, 2010; Kou et al., 2017; Gomes 
et al., 2018). Due to this last feature, the patient has to take extreme precautions from 
environmental light exposure. The second generation of PSs emerged either from structural 
modifications made on the macrocycles of the first generation or from changes in the 
synthetic routes to generate new families of molecules. These new compounds, more similar 
to what is expected for an ideal PS, include chlorine or bacteriochlorin, benzoporphyrin (or 
new porphyrin derivatives), purpurins, texaphyrins and phthalocyanines (Kou et al., 2017; 
Gomes et al., 2018). Among these PSs, the phthalocyanines (Pcs) have drawn attention as 
promising antitumor phototoxic drugs. Besides various physicochemical characteristics that 
will be mentioned later, several Pcs coordinated to zinc, aluminum or silicon are very 
efficient generators of singlet oxygen (Paquette et al., 1991; Boyle et al., 1992; Margaron et 
al., 1996; Colussi et al., 1999). Afterwards, the third generation of PSs was developed to 
promote a higher and more specific accumulation of PS in target cells. The main strategies 
employed to achieve this objective involve PS binding to antibodies (Kudarha and Sawant, 
2017; Pereira et al., 2014a) or incorporation to nanocarriers (Abrahamse et al., 2017; Yang 
et al., 2017). 
In this review, among the extensive list of recognized PSs for cancer treatment, we 
focus on the characteristics of zinc(II) phthalocyanines (ZnPcs), as many variants of this type 
of photo-activable drugs with improved physicochemical and biological properties have been 












antitumor mechanism of action in 2D and 3D cell cultures, and the in vivo effectiveness as 
anticancer agents in animal models and clinical trials will be herein summarized. 
 
2. Physicochemical properties of zinc(II) phthalocyanines  
2.1. Zinc(II) phthalocyanines for PDT 
Phthalocyanines are synthetic dyes that were first obtained by Braun and Tcherniac 
in 1907. Pcs are aromatic heterocycles that consist of four units of isoindoles bridged by 
nitrogen atoms. They have a characteristic UV-visible absorption spectrum with two main 
bands: the weak Soret band located in the UV zone of the spectrum at ~350 nm and the Q 
band, located in the red zone of the visible spectrum at around 680 nm, whose high intensity 
is one of the main characteristics of these dyes with a molar extinction coefficient of 1x105 
M-1 cm-1, two orders of magnitude higher than most porphyrins (Leznoff and Lever, 1989). 
Their photochemical properties are strongly influenced by the nature of the coordinated 
central metal ion. Thus, the presence of diamagnetic elements in the central cavity, such as 
zinc (II), aluminum (III), gallium (III) or silicon, gives them high triplet quantum yields ( 
T> 0.4) with long triplet lifetimes (T> 100 s) and adequate triplet energies (ET1 = 1.2 eV), 
making them efficient generators of singlet oxygen (> 0.4 (Lagorio et al., 1993).  
           ZnPcs have advantageous characteristics including low dark toxicity, high chemical 
and photochemical stability, high therapeutic effect, minimal skin photosensitivity and 
excitation at wavelengths greater than 630 nm, which allows greater tissue penetration of 
radiation (Jori, 1992; Marino et al., 2010). Despite these attractive features, one disadvantage 
of Pcs is their poor solubility in organic solvents (Nyokong and Antunes, 2010).  Their 
solubility can be increased by introducing peripheral ( position) and non-peripheral 
(position) substituents in the Pc framework (Figure 1). The tetrasubstituted Pcs are usually 












dipole moment resulting from the asymmetric rearrangement of the substituents (Leznoff et 
al., 1985). However, the four possible structural isomers of a tetrasubstituted Pc are difficult 
to separate and purify (Hanack et al., 1993).            
               On the other hand, the formation of aggregates in solution decreases the capacity 
to produce singlet oxygen because the photochemical activity is exclusively related to 
monomer species. Thus, aggregates decrease not only the photoactivity of the PS but also 
limit the access to the neoplastic cells, affecting its bioavailability. The presence of bulky or 
electrically charged peripheral substituents bound to the macrocycle and/or axial ligands 
coordinated to the central metal minimizes the tendency to form aggregates (García Vior et 
al., 2009, Wang et al., 2012; Muli et al., 2015). Ke et al. (2009) demonstrated that tetra-α-
substituted ZnPcs exhibit a reduced aggregating trend, higher photostability and enhanced 
photocytotoxicity toward human gastric carcinoma cells than the tetra-β-substituted 
counterparts. Our group also showed a similar behavior when the photodynamic effect of  
and  cationic substitution of ZnPcs was studied in human nasopharynx KB carcinoma cells 
(Marino et al., 2010). 
             In order to improve water solubilization of ZnPcs, the synthesis of anionic 
derivatives containing sulfonic (Haywood-Small et al., 2006; Lan et al., 2016), phosphonic 
(Venkatramaiah et al., 2015) or carboxylic groups (Zhou et al., 2016) has been carried out. 
For instance, Zhou et al. (2016) demonstrated that a ZnPc substituted with 16 COOH groups 
existed in its monomeric form under physiological conditions and showed superior 1O2 
generation than other derivatives containing less COOH groups. To control the degree of 
aggregation in aqueous media, Ikeuchi et al. (2016) synthetized a water-soluble ZnPc bearing 
four 3-sulfone-linked propylsulfonyl at non-peripheral positions. Other authors have also 
demonstrated the importance of positive charges in ZnPcs (Wood et al. 1997, Li et al., 2008; 












photophysical properties of cationic bioisosteric ZnPcs containing peripheral chains bound 
to the macrocycle by oxygen, sulfur or selenium (García Vior et al., 2009; Marino et al. 2010; 
Gauna et al., 2011, Ezquerra Riega et al., 2018). A bathochromic shift of 8–10 nm for the Q-
bands of ZnPcs was observed when sulfur or selenium were present, allowing the excitation 
of PSs in deeper regions of a tissue. In addition, although selenium ZnPcs reported the highest 
value of quantum yield of , both selenium and sulfur substituted ZnPcs showed similar 
phototoxic activities in colon carcinoma cells (Ezquerra Riega et al., 2018).  
2.2. Third generation zinc(II) phthalocyanines   
Even though lipophilic PSs show an increased tumor to normal tissue ratio (Stockert 
et al., 2004), the intravenous administration is difficult. To overcome this issue and avoid 
post-PDT skin photosensitivity, the so-called third generation PSs have been developed. 
They comprise second generation PSs associated to a carrier able to promote PS 
accumulation in tumor cells, to reduce aggregation tendency and minimize localization in 
normal cells. On these bases, formulation of ZnPcs in different nanosized delivery systems 
has been attempted. In the last years the most studied carriers include liposomes (de Oliveira 
et al., 2010; Garcia et al., 2011; López Zeballos et al., 2013; Kim et al., 2014), polymeric 
micelles (García Vior et al., 2013; Pucelik et al., 2016; Lamch et al., 2016; Debele et al., 
2017) and different types of nanoparticles (NPs) (Camerin et al., 2010;  Ping et al., 2016; 
Oluwole et al., 2016; Yurt et al, 2017), all of which showed an increase in the bioavailability, 
stability and transport of ZnPcs to the target tissue. Our group, after studying the 
incorporation of a lipophilic tetrasubstituted ZnPc into polymeric micelles and different 
liposomes, demonstrated a similar increase in solubility for both carriers, but a higher 
photodynamic activity against tumor cells in micellar formulations (López Zeballos et al., 
2013; García Vior et al., 2013; Chiarante et al., 2017). ZnPc molecules have been also 












al., 2016; Huang et al., 2016), TiO2 NPs (Yurt et al, 2017; Lopez et al., 2010), gold NPs 
(Camerin et al., 2010; Manoto et al., 2017a; Mfouo-Tynga et al., 2018a, 2018b; Dube et al., 
2018; Garcia Vior et al., 2019) and silica based NPs (Tu et al., 2012; Oluwole et al., 2016). 
Ricci-Junior et al. (2018), after evaluating the photobiological activity of three nanosystems 
(nanoparticles, nanoemulsions and mesoporous silica) containing ZnPc, demonstrated that 
all of these formulations could be used for clinical purposes in PDT. Furthermore, 
upconverting nanoparticles (UCNPs), based on the absorption and conversion of near 
infrared light to visible photons that can further activate the PS, have been efficiently 
employed as PDT carriers for ZnPcs (Guo et al., 2010; Tian et al., 2013; Wang H. et al., 
2014a; Hou et al., 2015). 
Targeting moieties that recognize specific sites expressed in tumor cells have been 
coupled to nanocarriers to improve ZnPcs accumulation. For instance, ZnPcs surrounded by 
a carbohydrate shell of galactose (Pereira et al., 2014b) or lactose (García Calavia et al., 
2018) units have shown to increase tumor selectivity, since cancer cells are known to 
overexpress carbohydrate-binding proteins, such as galectin-1 and the glucose GLUT-1 
transporter. Folic acid incorporated into micelles (Liang et al., 2014a) or UCNPs (Cui et al., 
2013) has been employed for targeting cancer cells overexpressing folate receptor. Wang H. 
et al. (2014b) demonstrated the efficacy of ZnPc and UCNP encapsulated into lipid micelles 
carrying cell-penetrating peptides. Likewise, ZnPcs conjugated with peptides or antibodies 
directed to EGFR have been properly incorporated by cells overexpressing EGFR (Ongarora 
et al., 2012a; Broekgaarden et al., 2016a). UCNPs conjugated with ZnPc and the monoclonal 
antibody Trastuzumab were designed by Ramirez Garcia et al. (2018) for specific HER2-
positive breast cancer detection and PDT. 
 












3.1. ROS formation, cellular uptake and intracellular localization  
As already mentioned, an appropriate PS should be capable of inducing an efficient 
formation of ROS after being irradiated. Among these phototoxic species, the main reacting 
species in vivo seems to be singlet oxygen (Agostinis et al, 2011; Gomes et al., 2018). 
Although this species has short life-time and short radius of action, cell damage is initiated 
in the intracellular sites where the PS is localized. Consequently, the oxidative damage 
begins the cascade of molecular events that finally lead to cell death (Oleinick et al., 2002; 
Chiu et al., 2010; Kessel, 2004). Based on the complexity imposed by cellular models, the 
ability of PSs to generate ROS has to be tested not only in fluid media but also in cellular 
environments. To this end, intracellular ROS content can be measured by using a fluorescent 
probe, such as 2´,7´-dichlorfluorescein-diacetate (DCFH-DA). This probe, after diffusing 
into cells, is deacetylated by esterases and then oxidized to the fluorescent 2´,7´-
dichlorfluorescein (DCF) in the presence of ROS (mainly hydrogen peroxide and lipid 
hydroperoxides). DCF fluorescence is in general detected by fluorescence microscopy, flow 
cytometry or with a fluorometer. All the ZnPc-based photosensitizers studied so far in cell 
cultures showed high ROS generation quantum yields, revealing that they behave as 
competent PSs for PDT applications (Yu W et al., 2018; Nag et al., 2018; Wang et al., 2017; 
Lu et al., 2016). In spite of this property, it should be taken into account that tumor hypoxia 
might reduce the antitumor efficacy of PDT due to the activation of the hypoxia-inducible 
factor 1 (HIF-1). In this regard, it was demonstrated that combined treatments of ZnPc 
with a HIF-1 inhibitor improved PDT efficacy in human carcinoma cells (Weijer et al., 
2016; Broekgaarden et al., 2016b).  
 The intracellular PS location, which determines both the primary site of photodamage 
and the mechanisms of cell death, is markedly influenced by the structural characteristics of 












dependent process. These fluorescent dyes are distributed homogeneously in the cytosol, as 
shown by confocal microscopy studies, and no evidence of nuclear localization has been 
detected. The mechanism of ZnPcs internalization seems to be dependent on the vehicule 
used to dissolve the PS. In this sense, Soriano et al. (2013) demonstrated that caveolin-
mediated endocytosis was responsible for internalizing a ZnPc dissolved in 
dimethylformamide, while an endocytic pathway dependent on clathrin mediated the 
incorporation of ZnPc included in liposomes.  
By using organelle-specific fluorescent probes, ZnPcs have been mainly found in 
mitochondria, lysosomes, endoplasmic reticulum (ER), plasma membrane or Golgi 
apparatus (GA) (Figure 2). Despite the variety of studies on the main sites of intracellular 
accumulation of ZnPcs, it is still not very simple to establish a clear relationship between the 
subcellular localization and the structural characteristics of these PSs. For instance, by 
working with an unsubstituted ZnPc, Fabris et al. (2001) showed that a liposomal formulation 
of the PS mainly localized in GA and plasma membrane after 2 h of incubation with 
transformed fibroblast, whereas both GA and mitochondrial localization were found after 24 
h of exposure. Soriano et al. (2014), using a liposomal formulation of the same PS in HeLa 
cells, reported a similar intracellular localization after short incubation periods. Although 
these results suggested that the incubation time is a variable that must be considered in 
subcellular localization studies, Cristobal et al. (2006) found that a ZnPc/liposomal 
formulation localized in GA, but not lysosomes or mitochondria, after either 3 or 18 h of 
incubation with lung carcinoma cells.  
The localization of a ZnPc dissolved in dimethylformamide or incorporated into a 
network of titanium dioxide was studied by Lopez et al. (2010) after 24 h of incubation in 
different cell lines. These authors reported an exclusive mitochondrial or lysosomal 












aid of specific organelle-probes, concluded that the unsubstituted ZnPc solubilized in the 
Cremophor EL formulation mainly localized in mitochondria, lysosome and ER after 24 h 
of incubation with hepatocellular carcinoma cells. Based on the dissimilar findings found 
with different formulations of unsubstituted ZnPc, it is possible to conclude that either the 
intrinsic properties of each formulation, the type of cell, the incubation time or the fluorescent 
probes employed to detect subcellular organelles could influence the results obtained.  
Regarding studies performed with substituted ZnPcs, Wood et al. (1997) showed that 
while anionic and cationic polysubstituted ZnPcs localized in lysosomes, neutral ZnPcs 
accumulated in GA. Afterwards, a great number of reports showed that either mono or 
polysubstituted ZnPcs target mainly to mitochondria and/or lysosomes, and in a lower degree 
to ER. In this regard, the mitochondrial and lysosomal localization of mixed sulfonated ZnPc 
(ZnPcSmix) has been shown in different cell types (Manoto et al, 2012; Manoto el al, 2013; 
Mfouo-Tynga et al., 2013; Sekhejane et al, 2014). The same distribution pattern was 
observed by Li et al. (2012) working with ZnPc-(Lys)n, a group of amphipathic 
monosubstituted ZnPcs conjugated to different numbers of lysine residue. Therefore, both 
mitochondrial and lysosomal localization have been reported for either negatively or 
positively charged PSs. Similarly, independently of the charge or the 
hydrophobic/hydrophilic nature of the PS, just a lysosomal accumulation was reported for 
hydrophobic ZnPcs, such as sulfur-linked octaalkylamino substituted ZnPc (Rumie Vittar et 
al., 2008), methoxy (Yslas et al., 2007) or amine-terminated monosubstituted ZnPcs (Peng 
et al., 2017), and hydrophilic ZnPcs, as cationic sulfur-linked (Gauna et al., 2011) or arginine 
substituted ZnPcs (Wang et al., 2017).  
A series of cationic ZnPcs conjugated to a bifunctional peptide were only found in 
lysosomes (Sibrian-Vazquez et al., 2007). On the other hand, Ge et al. (2013) reported the 












ammonium salt on the periphery, whereas Muli et al. (2008), based on the properties of 
rhodamine B to target mitochondria, described the synthesis and characterization of 
asymmetric ZnPc-rhodamine B conjugates for selective mitochondrial targeting. Duan et al. 
(2010) also showed a selective affinity to the mitochondria of a non-ionic 2-
(dimethylamino)ethylthio ZnPc. In addition, the effect of the formulation on the intracellular 
localization of ZnPcs should not be neglected. In this sense, Lan et al. (2016) described a 
restricted mitochondrial localization or a mitochondrial/lysosomal localization for a ZnPc 
substituted with sulfonated quinolineoxy groups and formulated either with Cremophor EL 
or PBS. It should also be considered that the exclusive mitochondrial localization of ZnPc-
based PSs found in several reports responds to the employment of just a specific 
mitochondrial probe (Oluwole et al., 2017; Ke et al., 2017; Huang et al., 2016; Lo et al., 
2007; Alexandratou et al., 2005).  
Our group demonstrated a lysosomal localization of a water-soluble tetrasubstituted 
ZnPc replaced with sulfur-linked cationic aliphatic chains in the human nasopharynx KB 
carcinoma cell line (Marino et al., 2010). The same cationic phthalocyanine targeted 
lysosomes and mitochondria in murine melanoma cells (Valli et al., 2019), reinforcing the 
concept that the intracellular location may vary according to the cell line studied. We also 
reported a preferential lysosomal localization of a lipophilic ZnPc (Pc9: tetrakis-[(2-
dimethylamino)ethylsulfanyl]phthalocyaninatozinc(II)) loaded either into liposomes or 
poloxamine micelles in KB cells (García Vior et al., 2013; López Zeballos et al., 2013). Since 
both formulations showed different phototoxic potencies (IC50 values were in the range of 
0.21-0.47 μM for Pc9-loaded into liposome formulations and 9.5-22 nM for Pc9-micelles 
formulations), the results herein obtained suggested that PS location was independent of the 
vehicle used and other factors, such as a differential uptake, could explain the variation in 












the intracellular fate of the PS did depend on the nature of the vehicle used. In this case, when 
the location of an unsubstituted ZnPc internalized in liposomes or BSA was studied, 
ZnPc:BSA preferentially located in GA, while the liposomal formulation was mostly located 
in the cellular membrane. In the last years, as interest in the role of ER in phototoxic cell 
death increased, various studies focused on this organelle as possible localization site. 
However, it must be taken into account that while lysosomal and mitochondrial probes have 
been extensively used for the study of ZnPcs, ER probes have been employed to a lesser 
degree. As mentioned before, Shao et al. (2013) verified the ER location of a 
ZnPc/Cremophor formulation by using an ER fluorescent Tracker. Likewise, when Manoto 
et al. (2012) demonstrated the mitochondrial and lysosomal distribution of ZnPcSmix in 
different tumor cell types, they also verified the absence of co-localization in the ER with a 
specific probe. Ongarora et al. (2012b), after studying the subcellular distribution of a series 
of cationic ZnPcs in tumor cells, showed that although these compounds localized in multiple 
sites within the cell (such as mitochondria, lysosomes, ER and GA), the most active ones -
containing a PEG group- were mainly found within the ER, suggesting that pegylation could 
favor the intracellular localization in the ER. Fujishiro et al. (2018) also reported that a 
cationic ZnPc carrying N-methyl-pyridinium groups was observed in greater amounts in the 
ER, Golgi, and lysosomes, whereas Kiew et al. (2017), working with a ZnPc conjugated to 
poly-L-glutamic acid, revealed a high co-localization in lysosomes and partial co-
localization with the ER and mitochondria. In our laboratory, we explored the intracellular 
distribution of a micellar formulation of a lipophilic ZnPc in CT26 colon cells, and found 
preferential photosensitizer incorporation into lysosomal vesicles and ER cisterns, but not 
mitochondria (Chiarante et al., 2017).  
In summary, since the subcellular localization of PSs is directly related to the 












the subcellular localization of ZnPcs, using a complete battery of organelle-specific probes, 
is an important step to achieve a clear understanding of the type of cell death. 
 
3.2. Mechanisms of cell death 
The photo-oxidative damage caused by PDT in tumor cells may activate different 
modalities of cell death, which can act independently, simultaneously or in combination, 
depending on the nature of PS, the administered dose, the cell type and the light exposure 
dose. Accordingly, for each tumor cell line treated under specific experimental conditions 
with a particular type of PS, the intracellular localization of the PS strongly determines the 
mode of cell death. The most frequent cellular responses induced in 2D or 3D cultures after 
PDT treatment include apoptosis, necrosis and autophagy (Butyaert et al., 2007; Agostinis et 
al., 2011; Mroz et al., 2010) (Figure 2). More recently, but only in 2D cultures, paraptosis 
has been described as a type of cell death induced by PSs that target the ER for photodamage, 
but it has not been described yet for ZnPcs (Kessel, 2018; Kessel and Oleinck, 2018; Kessel, 
2019). Apoptosis has been recognized as a frequent mechanism associated to the photo-
oxidative damage induced by PDT (Buytaert et al., 2007) and has been extensively 
characterized after ZnPc-induced photodamage. This cell death programme is mediated 
through the activation of either death receptor or mitochondrial-dependent pathways 
(extrinsic and intrinsic pathways, respectively), usually regulated by caspases (Grütter, 2000; 
Kaufmann and Hengartner, 2001; Galluzzi et al., 2012). 
3.2.1. Death receptor-dependent apoptosis: although the extrinsic pathway of apoptosis can 
contribute to the PDT-induced apoptotic response (Butyaert et al., 2007), few evidence of 
the involvement of this pathway after photodamage triggered by ZnPcs are found. The 
activation of the receptor death machinery has been suggested by Machado et al. (2009) who 
showed that Fas dimerization induced by p38MAPK activation in tumor cells treated with a 












the other hand, the decrease of Fas levels reported by Xia et al. (2011), after PDT treatment 
with a tetra-α-(4-carboxyphenoxy) ZnPc, suggested indeed an alteration of the death receptor 
complex assembly. Therefore, it seems that more than a direct involvement of this pathway, 
some molecular signals induced after ZnPcs PDT could be responsible for the activation or 
inhibition of an extrinsic apoptotic response. 
3.2.2. Mitochondrial-dependent apoptosis: since mitochondrial homeostasis is essential for 
cell viability, the damage to this organelle after ZnPcs PDT has been extensively studied 
taking into account both the mitochondrial localization of PSs and a possible downstream 
effect due to the injury initiated at other subcellular locations. Caspases activation, 
deregulation in the expression levels of Bcl-2 family proteins, reduction of mitochondrial 
membrane potential, cytosolic release of cytochrome c, PARP cleavage and chromatin 
condensation, among others, have been characteristics widely explored following ZnPcs 
PDT (Figure 3). Thus, after treatment, activation of caspases 8 and 9, leading to the cleavage 
of procaspase 3, has been reported in different cell types (Shao et al., 2013; Wang Y et al., 
2014; Doustvandi et al., 2017; Wang Y et al., 2018a). A time- and dose-dependent increase 
of the executioner caspase 3 has been described after irradiation of both unsubstituted and 
substituted ZnPcs (Fabris et al., 2006; Shao et al., 2012; Kuzyniak et al., 2017). Interestingly, 
an apoptotic caspase-independent mechanism has been described after irradiation of a water-
soluble octakis(3-aminopropyloxy) ZnPc in a human breast adenocarcinoma cell line (Rumie 
Vittar et al., 2010). In this work, the authors showed that ZnPc PDT induces the translocation 
of the apoptosis-inducing factor (AIF) to the nucleus, a mediator involved in DNA 
fragmentation in a caspase-independent manner (Figure 3). Also noteworthy, Doustvandi et 
al. (2017), after exploring the apoptotic response induced by a ZnPc at different light doses, 
suggested that an increase in light dose could switch a caspase-independent apoptotic 












Regarding the involvement of other caspases, some insights have been reported about 
the role of caspase 2 after PDT with ZnPcs. Thus, Cristóbal et al. (2006) demonstrated that 
caspase 2 was rapidly activated after treatment with a ZnPc liposomal formulation 
exclusively located in GA and suggested that this activation preceded the disorganization of 
the organelle to trigger an apoptotic response. Later, Mfouo-Tynga et al. (2014), by using 
ZnPcSmix, showed that the proteolytic caspase 2 cleaves and activates Bid into its truncated 
form (tBid) to promote mitochondrial permeabilization. Other studies with substituted ZnPcs 
also demonstrated that Bid cleavage occurs after irradiation (Rumie Vittar el al., 2010; 
Marino et al, 2013; Chiarante et al., 2018), although, in most reports, caspase 8 and lysosomal 
proteases have been identified as the main enzymes responsible for Bid fragmentation 
(Butyaert el al, 2007; Kessel and Oleinick, 2018) (Figure 4).   
The unbalance in the expression levels of Bcl-2 family proteins unquestionably plays 
a role in the mitochondria-mediated cell death (Figure 3). A down-regulation of antiapoptotic 
Bcl-2 proteins (Machado et al., 2009; Dai et al., 2016; Doustvandi et al., 2017; Zamani et al., 
2018) and up-regulation of some apoptotic proteins, such as Bak (Liu et al., 2017) and Bax 
(Machado et al., 2009; Dai et al., 2016; Zamani et al., 2018), have been commonly informed 
after PDT treatment with different formulations of ZnPcs in a wide variety of cell types. In 
some cases, although Bax levels remained unchanged after irradiation (Marino et al., 2013; 
Kuzyniak et al., 2016), a clear translocation of this protein from cytosol to mitochondrial 
membrane suggested its involvement in the opening of mitochondrial pores (Rello-Varona 
et al., 2008; Acedo et al., 2014). As a consequence of changes in Bcl-2 proteins, ZnPcs PDT 
treatment leads to the loss of mitochondrial membrane potential regardless of the chemical 
nature of the PS employed (Alexandratou et al., 2005; Huang et al., 2005; Shao et al., 2013; 
Ge et al., 2013) and the release of apoptogenic molecules, such as cytochrome c, to the 












and nuclear translocation of other mitochondrial apoptogenic species, such as AIF, have also 
been demonstrated after irradiation of some substituted ZnPcs (Rumie Vittar et al., 2010; 
Wang Y et al., 2018a). 
3.2.3. Lysosomal membrane permeabilization: PSs mainly located in lysosomes are expected 
to permeabilize lysosomal membrane upon light activation and promote mitochondrial injury 
through the release of lysosomal proteases into the cytosol (Figure 4). The contribution of 
lysosomal enzymes to the apoptotic response following photodamage has been earlier 
described (Reiners et al., 2002; Cirman et al., 2004; Ichinose et al., 2006). In particular, the 
first reports of ZnPcs affecting lysosomal integrity involved fluorescence microscopy 
studies. These works showed either a loss of the fluorescent punctuate staining of the specific 
LysoTracker Green probe after irradiation of different tumor cells (Yslas et al., 2007; Rumie 
Vittar et al., 2008; Manoto et al., 2013) or the lost of the acridine orange probe from intact 
acidic lysosomes (Marino et al., 2013; Sun et al., 2017; Chiarante et al., 2018). Studies 
performed in our laboratory either with a cationic (Marino et al., 2013) or a lipophilic 
(Chiarante et al., 2018) ZnPc located in lysosomes revealed that PDT treatment promotes the 
cytosolic release of the lysosomal protease cathepsin D in a ROS-dependent manner, since 
the expression levels of cathepsin D significantly diminished in the presence of antioxidants. 
We further showed that Bid cleavage was inhibited in the presence of a Pepstatin A, a 
cathepsin D inhibitor, supporting a role of cathepsin D in Bid activation (Marino el al., 2013). 
In addition, the reduction of caspase 8 activity observed after incubation of ZnPc-treated with 
Pepstatin A supported the involvement of cathepsin D in caspase 8 activation (Chiarante et 
al., 2018) (Figure 4).  
3.2.4. ER stress: as a key organelle involved both in the folding and trafficking of newly 
synthesized proteins as well as in the maintenance of Ca2+ homeostasis, ER photodamage 












Kralova, 2012). In the field of ZnPcs, Yu L et al. (2018) reported the ER localization of a 
biotinylated glutathione-responsive ZnPc that triggers ER stress after light irradiation. 
Studies performed in our laboratory with a lipophilic ZnPc also showed that ER stress 
induced by PDT can be propagated to the mitochondrial apoptotic pathway (Chiarante et al., 
2018). In both reports, an increase of intracellular Ca2+ concentration and higher expression 
levels of ER stress marker proteins, such as BIP/GRP78 and CHOP/GADD153, were 
demonstrated after photoactivation (Figure 5). Remarkably, we also demonstrated that 
calpains, activated by the high cytosolic Ca2+ concentrations reached after ER stress, 
contribute to Bax proteolytic damage (Chiarante et al., 2018). This Bax fragmentation, as it 
was shown in other apoptotic processes, could favor the formation of a more apoptotic 
fragment (Toyota et al., 2003). 
3.2.5. Necrosis: the first works addressing the mechanism of tumor necrosis showed areas of 
necrotic degeneration in tumor tissues treated by PDT with unsubstituted ZnPcs (Milanesi et 
al., 1990; van Leengoed et al., 1994; Ruck et al., 1996; Winsborrow et al., 1997). Necrotic 
regions were also described following in vivo PDT treatment with more complex 
formulations of ZnPcs (Allémann et al., 1997; Hu et al., 1998; Porthilo et al., 2013). Since 
tumor necrosis was defined by the analysis of histological tumor sections or the macroscopic 
appearance of PDT-treated tumors, it should be taken into account that these necrotic areas 
do not actually reflect the mechanism of cell death. Indeed, in cell cultures, necrosis is 
characterized by several features, including extensive plasma membrane damage, cell 
swelling, release of cellular contents to the environment, swelling of cytoplasmic organelles 
and moderate chromatin condensation (Galluzzi et al., 2007). In the field of PDT, although 
several of the typical characteristics of necrosis were identified in tumor cell lines after 
treatment with ZnPc formulations, sometimes the necrotic process might be secondary to a 












considered that the necrotic cell death induced by photodamage predominates at high doses 
of PDT (Oleinick et al., 2002). In this regard, Yslas et al. (2007), by working with a 0.5 μM 
concentration of a substituted ZnPc, showed that PDT treatment can induce either necrosis 
or an apoptotic cell death depending on the light dose used. Thus, while an apoptotic pathway 
occurs mainly at a light dose of 11 J/cm2, necrosis predominates at 29 J/cm2. Similarly, 
Acedo et al. (2014) demonstrated that the simultaneous administration of a ZnPc and a 
cationic porphyrin changes the mechanism of cell death from apoptosis to necrosis when the 
light dose increases from 2.4 to 3.6 J/cm2. Interestingly, our group reported a dual apoptotic 
and necrotic response triggered by a sulfur-linked cationic ZnPc located both in lysosomes 
and mitochondria in melanoma cells. In this case, although necrosis increased at high light 
doses or PS concentrations, this type of cell death was also detected simultaneously with the 
activation of an apoptotic response after irradiating cells with 340 mJ/cm2 (Valli et al., 2019).  
Fabris et al. (2001) showed that necrosis represents the main mode of death of 
transformed fibroblasts incubated with a liposomal formulation of an unsubstituted ZnPc 
mainly localized in the GA and plasma membrane after short periods of incubation, whereas 
after 24 h of exposure, morphological changes typical of apoptosis were observed when the 
Pc was found in GA and also in mitochondria. Soriano et al. (2014) reported a necrotic cell 
death induced after PDT with a ZnPc located in the plasma membrane, but the induction of 
a process of regulated necrosis (necroptosis) when the PS is located in the GA. Kim et al. 
(2014) developed a liposomal delivery system to localize an hydrophobic ZnPc selectively 
into the plasma membrane and showed that a substantial membrane disruption occurs upon 
irradiation, leading to a necrosis-like cell death. Thus, in a broad sense, the occurrence of 
PDT-induced apoptosis or necrosis may depend on several factors, including the PS used and 
its intracellular localization, the light dose, incubation times, the cell type and even the nature 












evaluating the phototoxic activity of different ZnPcs liposomal formulations containing 
cholesterol, showed that the phototoxicity is totally dependent on the presence of cholesterol 
and cell death of irradiated tumor cells is consistent with necrosis. Later, García et al. (2016) 
revealed different mechanisms of cell death for ZnPcs, depending both on the delivery 
vehicle and the PS intracellular location, being apoptosis dominant for ZnPcs formulations 
preferentially accumulated in GA, and necrosis for those located in cell membrane. 
3.2.6. Autophagy: this process displays a dual role, since it may induce either a survival 
response or contribute to a death pathway (Butyaert et al., 2007; Kessel and Oleinik, 2018). 
In the field of ZnPcs, Yu et al. (2019) demonstrated that PDT treatment with an unsubstituted 
ZnPc and the autophagy inhibitor 3-methyladenine inhibited tumor growth in a model of 
tumor metastasis, indicating that autophagy indeed exerts a protective role. On the other 
hand, Mfouo-Tynga et al. (2018b), after PDT treatment of breast cancer cells with a novel 
formulation of ZnPcSmix and gold nanoparticle encapsulated dendrimers, showed an up-
regulation of ULK-1, an autophagy gene that has been reported to contribute to cellular 
damage and death. 
 
4. Photodynamic effect of ZnPcs in 3D cultures and in vivo assays  
In order to evaluate the contribution of the cellular environment, tumor vasculature 
and the immunological response in PDT efficacy, more complex tumor models, that resemble 
more closely what actually happens in the treatment of oncological diseases, are required. 
To this end, 3D spheroids, chicken chorioallantoic membrane and animal tumor assays have 
been employed to examine the antitumor efficacy of ZnPcs. 
 












These 3D cell aggregates represent models intermediate in complexity between 2D 
cultures and in vivo tumors (Sutherland et al., 1970). A few works employing MCTS showed 
that photoactivation of ZnPcs could efficiently reduce cell viability. Studies performed in our 
laboratory with a micellar formulation of a lipophilic ZnPc revealed that although an efficient 
phototoxic response was observed after treatment of colon tumor spheroids, almost a 40 
times higher IC50 value was obtained in 3D cultures with respect to 2D cell monolayers 
(Chiarante et al., 2017). Similar differences in the phototoxic response were observed by 
Manoto et al. (2015) between lung tumor spheroids and 2D cultures. Both groups also 
demonstrated the induction of an apoptotic response in MCTS (Chiarante et al., 2017; 
Manoto et al., 2013; 2015). In addition, the influence of tumor spheroids size has been 
explored. In this sense, it has been reported that MCTS with a size of 500 μm are more 
resistant to PDT as compared to MCTS with a size of 250 μm. Since oxygen pressure and 
nutrients gradually decrease from the spheroid surface to the core, and PDT is an oxygen 
dependent therapy, the resistance to PDT seen in spheroids might be due to the reduced 
amount of oxygen found in the inner region of larger MCTS (Madsen et al., 2006; Manoto 
et al, 2015). Furthermore, a different gene expression profile was observed after ZnPcSmix 
PDT of tumor cells grown as monolayers or MCTS, suggesting that different mechanisms of 
action would be involved in 2D or 3D cell photodamage (Manoto et al., 2017b). 
Tumor spheroids were also employed to evaluate the efficacy of different carriers to 
transport lipophilic ZnPcs. For example, natural membrane vesicles derived from tumor cells 
loaded with ZnPc (Lee et al., 2015) or nanocarriers prepared via ZnPc deposition on TiO2 
(Flak et al., 2017) exhibited high potential as drug delivery agents and behaved as efficient 
phototoxic agents in tumor spheroids. 
 












As an alternative in vivo model, tumor cells can be inoculated on the chicken 
chorioallantoic membrane of fertilized eggs to evaluate the antitumor and antiangiogenic 
effect of different compounds (Uchida et al., 1987; Shoin et al., 1991). A total occlusion of 
chorioallantoic membranes vessels and improved photodynamic properties were observed 
by Chin et al. (2014) after photoactivation of a substituted ZnPc. Obata et al. (2015) 
demonstrated a significant growth inhibition of B16-F10 tumor cells transplanted to 
chorioallantoic membranes of chick-embryos irradiated with trifluoroethoxy-ZnPc 
formulations conjugated with β-cyclodextrin. Likewise, Kuzyniak et al. (2016; 2017), by 
working with substituted ZnPcs, showed a significant reduction of tumor growth and changes 
in the vascular network of chorioallantoic membranes.  
 
4.3. Animal tumor models 
Pharmacokinetics studies and the in vivo efficacy of ZnPcs have been investigated in 
different murine tumor models. After systemic administration, the phthalocyanine content in 
tumor and normal tissues has been usually determined by spectrofluorometric analysis. Reddi 
et al. (1990) evaluated the pharmacokinetic properties of ZnPc in mice bearing transplanted 
MS-2 fibrosarcoma and showed an improved selectivity of tumor targeting when low density 
lipoproteins, instead of liposomes, were employed as drug delivery systems. The slow 
clearance of ZnPc by the tumor also suggested that PDT effectiveness can be maintained at 
relatively long time intervals after administration. As a result, an efficient tumor response 
was obtained when irradiation was performed at 70 h after ZnPc administration. Shopova et 
al. (1992) also showed the maintenance for 72 h of the concentration of a liposomal ZnPc 
formulation in tumor tissues of hamsters bearing induced or transplanted 
rhabdomyosarcoma. Similar results were obtained with zinc(II)-naphthalocyanines (ZnNcs) 












Different chemical modifications and vehicles have been employed to improve 
pharmacokinetics in mice, including increased tumor targeting and lower liver and spleen 
retentions. A study performed with unsubstituted ZnPc and octapentyl or octadecyl ZnPc 
derivatives in fibrosarcoma-bearing mice showed that the maximal concentration of 
phthalocyanines in tumors was reached at 24 h post-injection. In addition, a slight increase 
in the efficiency and selectivity of tumor targeting was obtained upon increasing the length 
of the alkyl chains protruding from the macrocycle (Fabris et al., 1997; Jori and Fabris, 1998). 
Thus, both derivatives showed an approximately 50-fold higher concentration in the tumor 
than in the peritumoral tissue (Fabris et al., 1997). As most of the hydrophobic 
photosensitizers, Pcs were accumulated in large amounts in the liver and were eliminated 
from the organism through the bile-gut pathway (Jori, 1990; 2004). When the biodistribution 
of two substituted ZnPcs was studied, the monosulphonated analogue ZnPcF12S1, which 
exhibited high phototoxicity in murine tumors, displayed faster hepatic clearance and lower 
retention by the spleen than the perfluorinated ZnPcF16 (Allémann et al., 1997). Camerin et 
al. (2010) reported the in vivo PDT efficiency of a gold NP loaded with a hydrophobic ZnPc 
derivative (C11Pc). This formulation exhibited good tumor selectivity after 24 h of injection 
(Camerin et al., 2010). Later, Camerin et al. (2016) described a different delivery vehicle 
based on the co-self-assembly of C11Pc and a polyethylene glycol derivative (PEG) onto 
gold NPs. The incorporation of PEG on the particle surface enhanced the half-life of the 
conjugate in the serum, improving the in vivo photodynamic therapy of amelanotic 
melanoma. The pharmacokinetic studies showed that the retention time of the conjugates 
both in the serum and in the tumor increased as compared with NPs functionalized with 
C11Pc alone. The conjugates were eliminated via the bile-gut pathway without observable 
toxicity. Milla et al. (2009) also showed that a liposomal formulation of a 












these findings, the absence of hepatic toxicity after treatment with substituted ZnPcs was 
demonstrated by monitoring the hepatic cytochrome P450 activity and the levels of serum 
glutamic-pyruvic transaminase (Larroque et al., 1996; Yslas et al., 2010). The lack of renal 
toxicity was also assessed by Yslas et al. (2010) by checking creatinine and urea levels.  
Light sources employed in PDT with ZnPcs include lasers between 670 and 700 nm, 
the wavelengths corresponding to their maximum absorption. ZnPcs and light dose-
dependent phototoxic action was demonstrated in different in vivo models (Reddi et al., 1990; 
Allémann et al., 1997). Yslas et al. (2009) evaluated the effect of a tetra-methoxy ZnPc 
liposomal formulation, employing different light doses. The highest PDT efficacy in a mouse 
mammary adenocarcinoma model was obtained for the maximal light dose evaluated in the 
study (210 J/cm2). Doses mostly employed in vivo for a variety of ZnPcs are in the range of 
150-400 J/cm2.  
In vivo studies demonstrated that, not only the photochemical properties of ZnPcs, 
but also tumor drug uptake, are important factors for an effective PDT. For instance, different 
PS tumor concentrations and phototherapeutic effects were observed in vivo for ZnNcs 
liposomal formulations that exhibited similar quantum yields of 1O2-formation in vitro 
(Shopova et al., 1994). Furthermore, maximum concentrations of ZnPcs were reached 24 h 
after intravenous PS administration in different tumor models (Shopova et al., 1992; 
Allémann et al., 1997; Jori and Fabris, 1998; Yslas et al, 2009; Camerin et al., 2010). In 
general, the photosensitizing effect of ZnPcs in vivo was demonstrated by a decrease of tumor 
volume (Larroque et al., 1996; Yslas et al., 2010; Camerin et al., 2010) and an increase in 
the survival time of treated animals (Shopova et al., 1992; 1994). In addition, apoptotic 
pathway (Fabris et al., 1997; Jori and Fabris, 1998; Yslas et al, 2009, 2010; Xu et al., 2014) 
and random necrosis (Fabris et al., 1997; Jori and Fabris, 1998; Rumie Vittar et al., 2008) 












It is interesting to mention that, when the interval of time between drug and light 
administration was reduced to 1 h or 3 h, signs of vascular damage were reported. For 
example, Bremner et al. (1999) evaluated the effects of water-soluble ZnPcs containing 
neutral, positive and negative side-chains in a murine fibrosarcoma model and showed that 
tumor growth delay was greater with a 1 h than with a 24 h time interval, being the positive-
charged ZnPc the most effective sensitizer. In this study, a reduction in blood flow was shown 
to be an important factor in PDT. The effect of PDT on vessels was evaluated by Fingar et 
al. (1993) in Sprague-Dawley rats. Release of eicosanoids, vessel constriction, venule 
leakage and increased tumor interstitial pressure, as well as tumor reduction, were observed 
with monosulfonated and tertiary butyl substituted ZnPcs after light exposure 24 h post 
photosensitizer injection. Vascular damage after PDT treatment of a murine melanoma with 
ZnPc was also reported by Camerin et al. (2010), who confirmed damage of blood capillaries 
and endothelial cells by electron microscopy. Nevertheless, increased expression of vascular 
endothelial growth factor (VEGF) and higher microvessel density were detected in animals 
exposed to PDT. VEGF up-regulation was proposed to be associated with PDT-induced 
hypoxia (Bhuvaneswari et al., 2007; Das et al., 2010), and may suggest a side effect of PDT 
promoting tumor recurrence after treatment (Xu et al., 2014). 
Novel carriers to transport and efficiently activate ZnPcs have been developed and 
tested in vivo. Lanthanide-dope upconversion nanoparticles coupled with a -carboxy ZnPc 
(Wang M et al., 2014) and other synthetic materials, such as layered double hydroxides 
bound to unsubstituted ZnPc or to the octasulfonate ZnPc, showed to be efficient PDT agents 
for tumor growth inhibition  (Liang et al., 2014b; Li et al., 2017). A tumor-pH-responsive 
photosensitizer, prepared by conjugating ZnPc with 2,4,6-tris (N, N-dimethylaminomethyl) 












fluorescence imaging of tumor sites, suggesting that this Pc may be employed for tumor 
treatment and theranostics (Yan et al., 2018a). 
To sum up, all the in vivo studies provided strong evidences for the clinical 
application of ZnPcs and its derivatives formulations in PDT for cancer treatment. As it was 
mentioned, critical parameters must be adjusted to obtain a proper PDT efficacy, such as the 
optimal PS dose, the interval between photosensitizer administration and time of irradiation, 
light dose and light dose rate.  
 
5. Toxicity studies and clinical trials  
The first clinical trials were performed with the ZnPc tetrasulfonate (ZnPcS4) for use 
in veterinary medicine. ZnPcS4 was initially administered to Swiss Webster mice to assess 
acute toxicity. Doses >100 mg/kg produced renal tubular nephrosis, resulting in acute 
toxicity and mortality. Based on these data, a phase I clinical trial of ZnPcS4-based PDT 
against spontaneous tumors in dogs was started at a dose of 0.25 mg/kg and irradiation with 
675 nm light (100 J/cm2) 24 h after PS intravenous injection (Borgatti-Jeffreys et al., 2005). 
This study demonstrated tumor response using doses of 0.25 mg/kg and no adverse effects 
were observed with ZnPcS4 doses up to 2 mg/kg. Then, a new phase I clinical trial with an 
enlarged cohort of dogs was performed (Borgatti-Jeffreys et al., 2007). The PDT efficacy 
was confirmed in both mesenchymal and epithelial tumors. Another study showed partial 
responses or complete remissions of squamous cell carcinoma of the head and neck in dogs 
and cats treated with ZnPcS4-PDT with no prolonged cutaneous photosensitization or 
adverse effects (Lucroy, 2006). 
In parallel, a repeated-dose toxicity study of ZnPc-based-PDT was performed in 
Wistar rats. The intravenous administration of di-sulfo-di-phthalimidomethyl ZnPc, known 












pigmentation in several important organs at 4 mg/kg/day. The no-observed-adverse-effect 
levels were 1.0 mg/kg in Wistar rats (Zhang et al., 2006) and 1.5 mg/kg in dogs (Liu et al., 
2007). Characterization studies with Photocyanine were performed in order to determine 
optimal light dose and drug dosage in a murine sarcoma S180 model. An inhibitory effect on 
tumor growth was observed for 2 mg ZnPc/kg when irradiation doses using a 670-nm laser 
increased in the range of 36-144 J/cm2. Vertical resection of irradiated tumors showed that 
the depth of local tissue necrosis was 5.7-7.5 mm (Xue et al., 2011). 
 
6. ZnPc-PDT combined strategies 
In the last years several works have focused on the employment of combined 
therapies in order to overcome the high failure rate of single-agent or single-regimen therapy. 
Multiple drug combinations for cancer aim to exploit the additive or synergistic effects 
obtained from the action of two species, resulting in an improved antitumor efficacy, reduced 
side effects, and retarded drug resistance. Thus, PDT coupled with chemotherapy agents has 
proven to be a promising combination treatment for some kinds of tumors (Brodin et al., 
2015). The encapsulation of ZnPc and doxorubicin (DOX) into nanovehicles linked to folic 
acid achieved a synergistic chemotherapy-PDT in tumor cells overexpressing folic acid 
receptors (Liang et al., 2015; Flak et al., 2017; Huang et al., 2018). ZnPc and DOX were also 
conjugated through acid-labile and redox-responsive disulfide linkers in polymeric micelles. 
The observation of DOX fluorescence in the nucleus and ZnPc in the cytoplasm 
demonstrated that acidic and reducing intracellular environments could trigger the release of 
drugs by cleaving the linkers (Gao and Lo, 2018). A synergistic cytotoxicity was therefore 
found for certain DOX:ZnPc ratios in tumor-bearing mice. ZnPc was also covalently 
conjugated with DOX by the sequence Thr-Ser-Gly-Pro. In this case, although the 












and reduced DOX cytotoxicity, the peptide was sensitive to the activity of a protease highly 
expressed on cancer-associated fibroblasts. As a consequence, an enhanced cytotoxicity was 
observed upon cleavage and illumination (Ke et al., 2017). Synergistic anticancer effects of 
PDT and chemotherapy were also demonstrated by the combination of ZnPc with docetaxel 
(Conte et al., 2013) or paclitaxel (Wang Y et al., 2018b). In addition, the simultaneous 
administration of two PSs, such as ZnPc and a cationic porphyrin, led to a potentiated 
antitumor effect in mice bearing amelanotic melanoma cells (Acedo et al., 2014). ZnPc-PDT 
has also been efficiently combined with a Bcl-2 inhibitor (Liu et al., 2017), an autophagy 
inhibitor (Yu et al., 2019), a cell cycle inhibitor (Yan et al., 2018b) or an immunostimulant 
agent (Marrache et al., 2013). In addition, the combination of the autophagy inhibitor 3-
methyladenine with ZnPc-PDT as an strategy for osteosarcoma treatment down-regulated 
the expression levels of death ligand-1 (PD-L1), inhibiting tumor growth in a model of tumor 
metastasis (Yu et al., 2019). Recent studies have pointed out the role of PD-1 and its ligand 
PD-L1 as the most critical immune checkpoint blocking T-cell response and promoting 
tumor growth (Herbst et al., 2014; Dermani et al., 2019). Thus, further studies of combined 
therapy with immune checkpoint blockade and ZnPc-PDT will broaden the possibility of 
enhancing the immune anti-tumor response.  
When ZnPcs were incorporated into systems employed for hyperthermia generation, 
such as carbon nanohorns and gold nanorods, enhanced PDT efficiency was obtained. In 
these systems, laser irradiation was useful to simultaneously activate the PS and 
hyperthermia surfaces (Zhang et al., 2008; Freitas et al., 2017). Similarly, 
magnetohyperthermia and PDT with ZnPcs incorporated into magnetic nanoemulsions or 
nanoparticles led to significant tumor regression (Primo et al., 2008; Bolfarini et al., 2012; 











strategies will undoubtedly contribute to finding better therapeutic options for cancer 
treatment in the near future. 
 
7. Conclusions  
Based on the properties that should posses an ideal PS, phthalocyanines have been widely 
employed as second generation sensitizers. In particular, many efforts have been made to 
develop medicinal Pcs with therapeutic efficacy. In the field of ZnPcs, the photophysical and 
photochemical properties, subcellular localization, phototoxic activity, mechanisms of cell 
death and improved targeting to tumor tissues have been the main topics explored. The 
simultaneous localization of some ZnPcs in lysosomes/mitochondria or lysosomes/ER seems 
to be optimal for cell photodamage and its potential as therapeutic agents. Although the most 
extensive mode of cell death characterized so far has been apoptosis, it is necessary to 
continue investigating the contribution of other death modalities, such as necrosis, autophagy 
or even paraptosis, a type of cell death not yet studied for ZnPcs. The search of new possible 
mechanisms of action may consequently contribute to novel applications for single or 
combined ZnPcs treatments. Up to this moment, there is an immediate need to increase the 
number of clinical trials evaluating ZnPcs. As a result, it would be possible to confirm 
preclinical studies and orientate future research. PDT has much to offer to cancer treatment 
due to its unique combination of tumor cytotoxicity, vessel occlusion and immune response 
with minimal side effects. A deeper understanding of the effects of PDT with ZnPcs could 
enable in the future the improvement of currently used protocols and the treatment of an 
increased number of oncological diseases.   
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Legends to Figures 
 
Figure 1. Chemical structure of ZnPc (A), α-tetrasubstituted ZnPc (B) and β-
tetrasubstituted ZnPc (C) 
 
Figure 2. Main intracellular sites of ZnPcs localization. After irradiation, ZnPcs promote 













Figure 3. Mitochondria membrane permeabilization (MMP) induced by deregulation in 
the expression levels of Bcl-2 family proteins leads to activation of either caspase- 
dependent and independent apoptosis. 
 
Figure 4. Contribution of GA photodamage and lysosomal membrane permeabilization 
(LMP) to the activation of the mitochondrial-dependent apoptosis.  
 
Figure 5. Involvement of ER stress induced by photoactivated ZnPcs in the mitochondrial 
apoptotic pathway. 
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